Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01872039
Other study ID # ACN-PD-2012001
Secondary ID
Status Completed
Phase Phase 4
First received June 5, 2013
Last updated November 13, 2015
Start date March 2013
Est. completion date January 2014

Study information

Verified date November 2015
Source Astellas Pharma Inc
Contact n/a
Is FDA regulated No
Health authority China: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

To compare the efficacy and safety of two dose adjustment regimens (i.e. weight-based and non-weight-based) for the treatment of Chinese hypertensive emergency patients.


Description:

This study is a prospective, multi-center, open-label, randomized and controlled study. Subjects are selected from hypertensive emergency patients with a BP (Blood Pressure) of >180/120mmHg (SBP/DBP) and accompany with end target organ damage. All subjects are randomized into two groups receiving the Nicardipine Injection: Control Group (at a weight-based dose adjustment, i.e. according to the current Package Insert approved by SFDA) and Study Group (at a non-weight-based dose adjustment, i.e. according to the Package Insert approved by FDA).

Patients meet the inclusion/exclusion criteria are randomly allocated at 1:1 proportion to Control Group and Study Group. Before the treatment, investigators should define the target BP value for every subject according to different illness state, According to the BP, the dose of Nicardipine Injection is adjusted through different methods until reaching of target BP value. After reaching target BP value or 60min after the dosing initiation, BP and pulse rate are measured every 5~15min for 2h. Two to six hours after dosing, BP should be controlled at 160/100~110mmHg, and the maintenance dose is determined by the investigators according to the illness state.


Recruitment information / eligibility

Status Completed
Enrollment 163
Est. completion date January 2014
Est. primary completion date January 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Systolic blood pressure (SBP) =180mmHg and/or diastolic blood pressure (DBP) =120mmHg, and with the evidences or manifestations of end-organ damage (i.e. with any following hypertension emergency symptom: Chest pain, short breath, upper abdominal discomfort, syncope, vertigo, blurred vision, consciousness, hematuria or ischemic change under 12-lead ECG)

- Able to and voluntary to complete this study according to this study protocol, and sign the Informed Consent Form by himself/herself (or via his/her legal guardian)

Exclusion Criteria:

- Allergy to the Nicardipine Injection or its compositions

- Serious aortic valve stenosis

- Peri-operative hypertension

- Cerebral hemorrhage caused by the cerebrovascular malformation, hemangioma or cerebral infarction, cerebral hemorrhage into cerebral ventricle, and cerebral trauma with concomitant cerebral hemorrhage

- Other possible influencing factors for the safety or efficacy judgment in the investigators' opinions

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Perdipine injection
IV

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Astellas Pharma China, Inc.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of patients with target BP The target BP value is defined by investigators for every subject according to different illness state After 60 minutes of the treatment No
Secondary Blood pressure after the 6 hour treatment At 6 hours No
Secondary The time to get target BP The target BP value is defined by investigators for every subject according to different illness state Within 2 hours after treatment No
Secondary Safety assessed by the incidence of adverse events, vital signs and labo tests For 6 hours No